SEQUENT LAB LIMITED

🇬🇧Royaume-Uni•Private Limited Company (Ltd.)•Dissous

Ratio d'équité (2024)Ratio d'équité

100 %

Total actifs année sur année (2023 vs 2024)Total actifs année sur année

-59,5 %

TCAC total actifs (2021–2024)TCAC total actifs

Résumé

PaysRoyaume-Uni

StatutDissous

Numéro d'enregistrement12529433

Fondée23/03/2020

ObjectifManufacture of watches and clocks; Non-trading company

AdresseBoston House, 2a Boston Road, Henley-On-Thames, Oxfordshire, RG9 1DY

Déclaration de confirmationProchaine échéance: 05/04/2025; Dernière invention: 22/03/2024

Juridique et statut

Forme juridiquePrivate Limited Company (Ltd.)

StatutDissous

Date d'inscription23/03/2020

Autorité de registreCompanies House

Capital social100 £GB

Source : UK Companies House · Dernière mise à jour : 02/12/2025

Chronologie (13 événements)

01/11/2024

Statut modifié

active → active - proposal to strike off

02/04/2024

Dépôt des comptes annuels

Total exemption full accounts made up to 29 February 2024

Voir le fichier dans Documents

23/03/2020

Nomination Adrian Buchmann (personne)

Nommé en tant que Director

Métrique	2021	2022	2023	2024
Total des actifs	£100	£37 933	£72 247	£29 274
Net Assets Liabilities	£100	—	—	—
Equity	£100	£37 933	£72 247	£29 274
Current Assets	—	—	£122 463	£31 093
Net Current Assets Liabilities	—	£37 933	£72 247	£29 274
Total Assets Less Current Liabilities	—	£37 933	£72 247	£29 274
Cash Bank On Hand	—	—	£0	£13 828
Debtors	—	£48 127	£122 463	£17 265
Other Debtors	—	£48 127	£122 463	£17 265
Creditors	—	£10 194	£50 216	£1 819
Other Creditors	—	£1 320	£2 016	£1 776
Number Shares Allotted	100	—	—	—
Par Value Share	£1	—	—	—
Average Number Employees During Period	—	1	1	1
Amount Specific Advance Or Credit Directors	—	£48 076	£102 443	£12 825
Amount Specific Advance Or Credit Made In Period Directors	—	£48 076	£102 467	—
Amount Specific Advance Or Credit Repaid In Period Directors	—	£0	£48 100	£89 618
Called Up Share Capital Not Paid Not Expressed As Current Asset	£100	—	—	—
Other Taxation Social Security Payable	—	£8 874	£48 200	£43

Métrique

2021

2022

2023

2024

Total des actifs

£100

£37 933

£72 247

£29 274

Net Assets Liabilities

£100

—

Equity

£100

£37 933

£72 247

£29 274

Current Assets

—

£122 463

£31 093

Net Current Assets Liabilities

—

£37 933

£72 247

£29 274

Total Assets Less Current Liabilities

—

£37 933

£72 247

£29 274

Cash Bank On Hand

—

£0

£13 828

Debtors

—

£48 127

£122 463

£17 265

Other Debtors

—

£48 127

£122 463

£17 265

Creditors

—

£10 194

£50 216

£1 819

Other Creditors

—

£1 320

£2 016

£1 776

Number Shares Allotted

100

—

Par Value Share

£1

—

Average Number Employees During Period

—

Amount Specific Advance Or Credit Directors

—

£48 076

£102 443

£12 825

Amount Specific Advance Or Credit Made In Period Directors

—

£48 076

£102 467

—

Amount Specific Advance Or Credit Repaid In Period Directors

—

£0

£48 100

£89 618

Called Up Share Capital Not Paid Not Expressed As Current Asset

£100

—

Other Taxation Social Security Payable

—

£8 874

£48 200

£43

Nom	Participation	Droit de vote	Depuis

SEQUENT LAB LIMITED

Résumé

Juridique et statut

Chronologie (13 événements)

Statut modifié

Dépôt des comptes annuels

Nomination Adrian Buchmann (personne)

Réseau

Propriété et gestion

Persons with significant control

Officers & directors

Chronologie de la propriété (changements de 1)

Nomination Adrian Buchmann (personne)

Actionnaires

Bénéficiaire effectif

Géographie

Finances

Chiffres clés

Documents

Rapport d'entreprise de SEQUENT LAB LIMITED

Final Gazette dissolved via voluntary strike-off

First Gazette notice for voluntary strike-off

Strike off from register

Confirmation statement

Total exemption full accounts made up to 29 February 2024

Previous accounting period shortened from 31 March 2024 to 29 February 2024

Compulsory strike-off action has been discontinued

Total exemption full accounts made up to 31 March 2023

First Gazette notice for compulsory strike-off

Companexia Document AI

Parcourir plus d'entreprises & personnes

Santé financière

Croissance

Fonds de roulement et liquidité

Structure du capital